BioNTech
phase pharmacodynamic effects consistent with proposed mechanism of action in patients with who progressed on therapy | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2021
Slide
27 of 40
Related slides by other companies
Erasca
Investor Presentation
August 2023
eras phase responses observed in patients with ras and alterations in diverse tumor types with single agent schedule | Erasca
Nuvalent
Investor Presentation
February 2024
the path to patient impact program status first approved a toe pivotal data naive and study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in for her | Nuvalent
Exscientia
Investor Presentation
August 2023
ignite phase initiated in | Exscientia
Nuvalent
Investor Presentation
January 2024
the path to patient impact ams execute on global registrational strategies pivotal data program status study for phase ongoing with registrational intent for patients with and study for alk demonstrated clinical proof of concept in phase with planned development in both and alk for her planned phase initiation in additional discovery research programs ongoing first approved product mission bringing new best in class medicines to patients with cancer i | Nuvalent
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights